FI114636B - Förfarande för framställning av nya terapeutiskt användbara bensylaminokinuklidinderivat - Google Patents

Förfarande för framställning av nya terapeutiskt användbara bensylaminokinuklidinderivat Download PDF

Info

Publication number
FI114636B
FI114636B FI934626A FI934626A FI114636B FI 114636 B FI114636 B FI 114636B FI 934626 A FI934626 A FI 934626A FI 934626 A FI934626 A FI 934626A FI 114636 B FI114636 B FI 114636B
Authority
FI
Finland
Prior art keywords
carbon atoms
alkyl
compounds
formula
compound
Prior art date
Application number
FI934626A
Other languages
English (en)
Finnish (fi)
Other versions
FI934626A (fi
FI934626A0 (fi
Inventor
Kunio Satake
Fumitaka Ito
Kaoru Shimada
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI934626A0 publication Critical patent/FI934626A0/fi
Publication of FI934626A publication Critical patent/FI934626A/fi
Application granted granted Critical
Publication of FI114636B publication Critical patent/FI114636B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Claims (2)

1. Förfarande för framställning av nya terapeu-tiskt användbara bensylaminokinuklidinderivat med formeln 5 (I) ORI där Ar1 och Ar2 betecknar oberoende av varandra aryl eller substituerad aryl:
10 R1 är alkyl med 1-6 kolatomer; R är väte eller alkyl med 1-6 kolatomer; och X och Y betecknar oberoende av varandra väte, dialkylfosforyl med 2-12 kolatomer, alkyl med 1-6 kolatomer, alkenyl med 2-6 kolatomer eller alkynyl med 2 15 - 6 kolatomer; eller X och Y betecknar tillsammans en kol- vätekedja med 3, 4 eller 5 kolatomer och med högst 2 dub-, belbindningar och som kan ha 1 eller 2 substituenter, som är valda ur gruppen oxo, hydroxi och alkyl med 1-6 * 1 * ‘ · · kolatomer; V.’ 20 förutsatt att, da-X och Y tillsammans betecknar en kolvätekedja, sä är de bundna tili närliggande kolatomer; ; ’.· och förutsatt att, dä antingen X eller Y är väte, sä är den ena alkenyl eller alkynyl; och 25 förutsatt att, dä X och Y bildar tillsammans med ···, bensenringen en naftylgrupp, sä är R1 alkyl med 2-6 ko latomer, kännetecknat av att en förening med ; ’·· formeln S "ne : Ar* 28 114636 där Ar1, Ar2 och R2 betecknar samma som ovan, omsätts med en förening med formeln OR1 där R1, X och Y betecknar samma som ovan, i närvaro av ett 5 reduktionsmedel.
2. Förfarande enligt patentkrav 1, kanne-tecknat av att reaktionen utförs i närvaro av ett reduktionsmedel, som är trialkylboran eller NaBH(0Ac)3, i ett inert lösningsmedel. » « V • 1 · * 1 1 • » • 1 · • # » · » 1 t · t ·
FI934626A 1992-10-21 1993-10-20 Förfarande för framställning av nya terapeutiskt användbara bensylaminokinuklidinderivat FI114636B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28313592 1992-10-21
JP4283135A JP2656699B2 (ja) 1992-10-21 1992-10-21 置換ベンジルアミノキヌクリジン

Publications (3)

Publication Number Publication Date
FI934626A0 FI934626A0 (fi) 1993-10-20
FI934626A FI934626A (fi) 1994-04-22
FI114636B true FI114636B (sv) 2004-11-30

Family

ID=17661684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934626A FI114636B (sv) 1992-10-21 1993-10-20 Förfarande för framställning av nya terapeutiskt användbara bensylaminokinuklidinderivat

Country Status (16)

Country Link
EP (1) EP0665844B1 (sv)
JP (1) JP2656699B2 (sv)
AT (1) ATE196140T1 (sv)
AU (1) AU5165393A (sv)
CA (1) CA2146259C (sv)
DE (1) DE69329386T2 (sv)
DK (1) DK0665844T3 (sv)
ES (1) ES2149215T3 (sv)
FI (1) FI114636B (sv)
GR (1) GR3034498T3 (sv)
HU (1) HUT65133A (sv)
IL (1) IL107292A0 (sv)
MX (1) MX9306527A (sv)
PT (1) PT665844E (sv)
WO (1) WO1994008997A1 (sv)
ZA (1) ZA937780B (sv)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790825A1 (en) * 1994-11-10 1997-08-27 Pfizer Inc. Nk-1 receptor antagonists for the treatment of eye disorders
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE9290057U1 (de) * 1991-05-22 1994-01-05 Pfizer Substituierte 3-Aminochinuclidine

Also Published As

Publication number Publication date
ES2149215T3 (es) 2000-11-01
HUT65133A (en) 1994-04-28
PT665844E (pt) 2001-01-31
FI934626A (fi) 1994-04-22
DE69329386D1 (de) 2000-10-12
GR3034498T3 (en) 2000-12-29
JPH06135963A (ja) 1994-05-17
EP0665844A1 (en) 1995-08-09
MX9306527A (es) 1994-07-29
AU5165393A (en) 1994-05-09
CA2146259A1 (en) 1994-04-28
IL107292A0 (en) 1994-01-25
DK0665844T3 (da) 2000-10-16
DE69329386T2 (de) 2001-01-04
CA2146259C (en) 1998-04-07
HU9302965D0 (en) 1993-12-28
FI934626A0 (fi) 1993-10-20
EP0665844B1 (en) 2000-09-06
ZA937780B (en) 1995-04-20
JP2656699B2 (ja) 1997-09-24
ATE196140T1 (de) 2000-09-15
WO1994008997A1 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
FI114636B (sv) Förfarande för framställning av nya terapeutiskt användbara bensylaminokinuklidinderivat
FI114637B (sv) Förfarande för framställning av terapeutiskt användbara substituerade kinuklidiner
CA2132541C (en) Quinuclidine derivatives as substance p antagonists
EP0699199B1 (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
CA2086434C (en) Quinuclidine derivatives
EP0613458B1 (en) Acyclic ethylenediamine derivatives as substance p receptor antagonists
EP0573522B1 (en) 1-azabicyclo[3.2.2]nonan-3-amine derivatives
FI113654B (sv) Förfarande för framställning av terapeutiskt användbara azabicyklo[2.2.2]oktan-3-aminer
PL172069B1 (pl) Sposób wytwarzania nowych pochodnych podstawionej 3-aminochinuklidyny PL PL PL PL PL
IE83327B1 (en) Substituted 3-aminoquinuclidines
JP2009143956A (ja) アザビシクロアルキルエーテルおよびそのα７−ＮＡＣＨＲアゴニストとしての使用
US5604241A (en) Substituted benzylaminoquinuclidines as substance P antagonists
US5569662A (en) Quinuclidine derivatives as substance P antagonists
US5837711A (en) Substituted quinuclidines as substance P antagonists
US6143767A (en) Piperidinylamino tricyclic compounds as substance P antagonists
JP2822274B2 (ja) Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
AU2009304171B2 (en) Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1H-3-indazolecarboxylic acid amides
MXPA00004790A (es) Procedimiento para preparar 2-fenil-3-aminopiridina, derivados fenilo sustituidos de la misma y sales de dichos compuestos.
JPH059190A (ja) 二環性含硫黄化合物

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114636

Country of ref document: FI